Feb. 25, 2020 |
|
Oct. 07, 2024 |
|
jRCTs031190221 |
Hypothesis generative H2H study comparing the efficacy between afatinib and osimertinib based on the immunological biomarker in the NSCLC patients with EGFR mutations (HeaT ON BeaT) |
|
Hypothesis generative H2H study comparing the efficacy between afatinib and osimertinib based on the immunological biomarker in the NSCLC patients with EGFR mutations (HeaT ON BeaT) |
Seki Nobuhiko |
||
Teikyo University Hospital |
||
2-11-1 Kaga, Itabashi-ku, Tokyo |
||
+81-3-3964-1211 |
||
nseki@med.teikyo-u.ac.jp |
||
Tanzawa Shigeru |
||
Teikyo University Hospital |
||
2-11-1 Kaga, Itabashi-ku, Tokyo |
||
+81-3-3964-1211 |
||
shigen1025@yahoo.co.jp |
Not Recruiting |
Feb. 25, 2020 |
||
May. 12, 2020 | ||
100 | ||
Interventional |
||
randomized controlled trial |
||
open(masking not used) |
||
active control |
||
parallel assignment |
||
other |
||
1) Histologically or cytologically confirmed non-small, non-squamous cell lung carcinoma. |
||
1) History of interstitial lung disease or radiation pneumonitis. |
||
20age old over | ||
No limit | ||
Both |
||
EGFR-mutant non-small cell lung carcinoma with recurrent/advanced stage |
||
Group A: Afatinib 40mg/day |
||
Survival rate at 3 years |
||
Progression-free survival 1 |
Boehringer Ingelheim Japan, Inc. | |
Not applicable |
Yokohama City University Certified Institutional Review Board | |
3-9 Fukuura, Kanazawa-ku, Yokohama-city, Kanagawa | |
+81-45-370-7627 |
|
rinri@yokohama-cu.ac.jp | |
Approval | |
Feb. 17, 2020 |
none |